Oral antihyperglycemic therapy for type 2 diabetes: clinical applications

JAMA. 2002 Jan 16;287(3):373-6. doi: 10.1001/jama.287.3.373.

Abstract

Oral agents are the mainstay of pharmacologic treatment for type 2 diabetes, and physicians now have a number of agents to choose from. However, more choices translate into more complex decision making. Many patients with diabetes have associated comorbidities, and most diabetic patients will require more than 1 agent to achieve good glycemic control. This article illustrates several of the pharmacologic approaches to type 2 diabetes through 4 situations that use principles of evidence-based medicine. The scenarios also highlight some of the difficulties in choosing the optimal pharmacologic treatment regimen for individual patients. Physicians should also recognize that type 2 diabetes is a multisystem disorder that requires multidisciplinary care, including education and ongoing counseling for effective patient self-management of the disease. Finally, patient preferences are a vital component of informed decision making for pharmacologic treatment of diabetes.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biguanides / therapeutic use
  • Comorbidity
  • Decision Making
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Drug Therapy, Combination
  • Enzyme Inhibitors / therapeutic use
  • Evidence-Based Medicine
  • Female
  • Glycoside Hydrolase Inhibitors
  • Humans
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / therapeutic use
  • Male
  • Middle Aged
  • Patient Education as Topic
  • Patient Participation
  • Physician-Patient Relations
  • Practice Guidelines as Topic
  • Sulfonylurea Compounds / therapeutic use
  • Thiazoles / therapeutic use

Substances

  • Biguanides
  • Enzyme Inhibitors
  • Glycoside Hydrolase Inhibitors
  • Hypoglycemic Agents
  • Insulin
  • Sulfonylurea Compounds
  • Thiazoles